Ora

Executive Summary

Ora Biomedical is a San Diego-based company leveraging high-throughput live animal screening and machine learning to accelerate the discovery of therapies that enhance longevity and resilience. Founded in 2018, the company bridges fundamental science with translational breakthroughs by combining automated worm (C. elegans) assays with AI-driven data analysis. This platform enables rapid, cost-effective testing of thousands of compounds for effects on healthspan and lifespan, addressing a critical bottleneck in aging research. Ora's approach aims to identify novel drug candidates and biological pathways that could slow aging or increase stress resistance, with potential applications in age-related diseases and healthy longevity. The company's technology positions it at the intersection of AI and biotech, offering a unique tool for both basic research and drug development.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Publication of High-Throughput Screening Results in Peer-Reviewed Journal80% success
• TBDPartnership with Major Pharmaceutical Company for Target Validation50% success